News
News
PublISHED ON
UpDATED ON
Sweden participates in clinical WHO study
Sweden is participating in a major clinical study conducted by WHO, aimed at testing a number of antiviral medicines on patients around the world who are being treated for COVID-19.
Because more than 100 countries are taking part in the WHO study Solidarity Trial, the patient base is large. This makes it quicker to see whether any of the preparations are effective, and can begin to be used to treat the disease.
The Swedish Government recently appointed Soo Aleman, Consultant Physician at the Karolinska University Hospital and Associate Professor at Karolinska Institutet, to be the national coordinator for the Swedish part of the study. The Swedish Research Council will fund Swedish participation, as soon as the investment is formalized in the regulatory letter.
“It is important for Sweden to be part of the international study. Patients in Sweden who have suffered severe COVID-19 can now get access to potentially effective medicines. In the long term we will obtain greater knowledge of what is effective, which will also benefit patients who are not part of the study,” says Jan-Ingvar Jönsson, Secretary General of the Scientific Council for Medicine and Health and Clinical Therapy Research at the Swedish Research Council.
About the studie Solidarity trial on WHO´s website External link.
RELATERAT INNEHÅLL
MORE WITHIN THE SAME SUBJECT AREA
-
News |
Published 9 May 2025
Collaboration, early involvement of collaboration partners, and simplified contract management are important factors when it comes to clinical therapy research. This is shown in an analysis of the Swedish Research Council’s funding of the field over ...
Keywords:
-
News |
Published 14 April 2025
There is basic medical research in Sweden that is of very high quality and offers important solutions to societal challenges, particularly in health. This was established by the international panel that evaluated the research at seven universities, u...
-
News |
Published 13 February 2025
In April, we will open four calls for proposals, in addition to those previously announced for 2025.